The correlations between cytokine status, vascular endothelial growth factor (VEGF) content, clinical and biochemical parameters in patients with various forms of gout were studied to improve the algorithm for monitoring of clinical condition and effectiveness of treatment. For patients with gout and volunteers clinical and biochemical studies were performed. The content of interleukins (IL-1β, IL-17, IL-22, IL-10), tumor necrosis factor alpha (TNF-α) and VEGF were investigated. Concentrations of TNF-α, IL-1β and IL-17 characterized of inflammation intensity at all stages of gout and increased linearly as the disease progressed. At the stage of asymptomatic hyperuricemia, there were an increased (75% of the control group) concentration of IL-22 on the background of lymphopenia, low concentrations of IL-10 and VEGF. This indicates that the content of IL-22 is a potentially informative biomarker of inflammation intensity as well as a possible predictor of the development of immune-dependent complications and vascular catastrophes in the early stages of gout without signs of joint damage. The concentration of TNF-α positively correlates with the content of IL-10 (r = 0.534); whereas the concentration of IL-1β is independent of the content of IL-10. The relationship between IL-1β and VEGF concentrations (r = 0.40) suggests that IL-1β is more closely associated with endothelial dysfunction and the risk of vascular complications. IL-22 levels do not correlate with other cytokine status, but are associated with lymphocyte counts, so signs of Th22-dependent immune inflammation may be a potential biomarker of lymphocytic depression status in gout. Cytokine status changes in different phases and stages of hyperuricemia. Comparing these changes with the clinical and laboratory picture improves monitoring of the disease development and effectiveness of treatment.